All Stories

  1. Late-onset lupus nephritis: what is the evidence?
  2. Urinary proteomic profiling to identify early biomarkers of non-diabetic chronic kidney disease
  3. Insights From the UK on Fibromuscular Dysplasia in Pregnancy
  4. Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: A call to action from the cardio-kidney community
  5. Cardiorenal Syndrome in the Elderly: Challenges and Considerations
  6. Gum Hyperplasia in a Patient with Lupus Nephritis
  7. Optimization of Renin-Angiotensin-Aldosterone Inhibitor Therapies for Evidence-Based Indications: a Call to Action From the Cardio-Kidney Community
  8. Anti-nuclear cytoplasmic antibody-associated vasculitis and kidney cancer: A mini review
  9. Noninvasive Assessment of Urinary Exfoliated Proximal Tubule Cell Multispectral Autofluorescence May Differentiate between Causes of Kidney Transplant Dysfunction
  10. Considering the utility of urinary amino acids for early identification of non-diabetic chronic kidney disease
  11. Optimization of renin‐angiotensin‐aldosterone inhibitor therapies for evidence‐based indications: a call to action from the cardio‐kidney community
  12. Does Dialysis Modality Have a Role on Stroke Risk?
  13. Is There a Diagnostic and Prognostic Role for Anti-Nephrin Autoantibodies in Diabetic Nephropathy?
  14. Monkeypox infection in kidney transplant recipients
  15. WCN25-79 NON-INVASIVE DIAGNOSIS OF CHRONIC KIDNEY DISEASE BY MACHINE-LEARNING BASED EVALUATION OF URINARY EXFOLIATED PROXIMAL TUBULE CELL MULTISPECTRAL AUTOFLUORESCENCE
  16. Association Between Glycemic Control and Complications With Concentration of Urinary Exfoliated Proximal Tubule Kidney Cells in People With Diabetes Mellitus
  17. Pericardial cyst: an unexpected diagnosis in a patient presenting with breathlessness
  18. H5N1 Infection and Kidney Pathology: Is There a Link?
  19. Considering kidney replacement therapy initiation based on acute encephalopathy in severe acute kidney injury
  20. Characteristics of Inherited Metabolic Disorders Following Kidney Transplantation: A 13-Year Observational Study
  21. Evaluation of urinary volatile organic compounds as a novel metabolomic biomarker to assess chronic kidney disease progression
  22. Associations between frailty status and humoral response to SARS-cov-2 vaccination in kidney transplantation and dialysis
  23. Gut Microbiota in Patients Receiving Dialysis: A Review
  24. Lessons for the clinical nephrologist: fibromuscular dysplasia in older adults
  25. Infective Endocarditis in Patients Receiving Hemodialysis: A Current Review
  26. Unexpected seronegative response in relapsed PLA2R-associated membranous nephropathy
  27. 499-P: Association between Diabetic Retinopathy and Number of Urinary Exfoliated Proximal Tubule Kidney Cells
  28. Evaluating the Clinical Relevance of Antibodies against Non-Human Leukocyte Antigen in Kidney Transplantation
  29. Autosomal Dominant Polycystic Kidney Disease in Older Adults
  30. #328 Non-invasive assessment of urinary exfoliated proximal tubule cells using multispectral autofluorescence imaging features for early detection of CKD
  31. The Significance of Anti-PLA2R in Diabetic Kidney Disease: Truly a False Positive?
  32. WCN24-213 DIABETIC KIDNEY DISEASE AND NUMBER OF URINARY EXFOLIATED PROXIMAL TUBULE CELLS: IS THERE A LINK?
  33. Incidence, Risk Factors, and Outcomes of De Novo Malignancy following Kidney Transplantation
  34. Using Digital Health Interventions to Promote Prehabilitation Prior to Kidney Transplantation
  35. Clostridioides difficile Infection in Kidney Transplant Recipients
  36. Updates on Renal Replacement Therapy
  37. Hepatocardiorenal syndrome in liver cirrhosis: Recognition of a new entity?
  38. Hypertrophic Cardiomyopathy and Chronic Kidney Disease: An Updated Review
  39. Is home dialysis an optimal option during pregnancy?
  40. Frailty and antineutrophil cytoplasmic antibody‐associated vasculitis: What do we know?
  41. Prophylactic ultra-low dose rituximab to maintain remission in relapsing adult minimal change disease
  42. How I Treat Elderly Patients with Kidney Failure with Peritoneal Dialysis
  43. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes
  44. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  45. Weighing up telehealth for older adults receiving home dialysis
  46. The Role of PLA2R in Primary Membranous Nephropathy: Do We Still Need a Kidney Biopsy?
  47. COVID-19 Infection and Vaccination and Its Relation to Amyloidosis: What Do We Know Currently?
  48. Delivering Personalized, Goal-Directed Care to Older Patients Receiving Peritoneal Dialysis
  49. #4146 LIMITATIONS AND UNCERTAINTIES OF ASSESSING AND MANAGING OLDER PATIENTS WITH ANCA ASSOCIATED VASCULITIS
  50. #5507 ANTIHYPERTENSIVE PRESCRIBING PATTERNS IN CKD: FINDINGS FROM THE SALFORD KIDNEY STUDY
  51. Seizures and chronic kidney disease: An in-depth review
  52. Physiological Associations between Vitamin B Deficiency and Diabetic Kidney Disease
  53. COVID-19 in Elderly Patients Receiving Haemodialysis: A Current Review
  54. Big Data in Chronic Kidney Disease: Evolution or Revolution?
  55. Is It Time to Integrate Frailty Assessment in Onconephrology?
  56. Prescribing Immunosuppressive Treatment for Older People with Glomerular Diseases: Time to Assess Frailty?
  57. Merkel Cell Carcinoma in Kidney Transplant Recipients
  58. Stenotrophomonas maltophilia: A Case Series and Review for an Uncommon Cause of Peritoneal Dialysis-Associated Infection
  59. Impact of frailty status on clinical outcomes in patients receiving peritoneal dialysis
  60. Peritoneal dialysis‐associated peritonitis presenting with Ralstonia pickettii infection: A novel series of three cases during the COVID‐19 pandemic
  61. Improving physical functioning and activity of elderly peritoneal dialysis patients
  62. COVID-19 and hepatorenal syndrome
  63. Home dialysis in older adults: challenges and solutions
  64. Intrinsic Kidney Pathology in Children and Adolescents Following COVID-19 Vaccination: A Systematic Review
  65. Pruritus in Chronic Kidney Disease: An Update
  66. Is HIF-PHI the Answer to Tackle ESA Hyporesponsiveness in the Elderly?
  67. Exfoliated Kidney Cells from Urine for Early Diagnosis and Prognostication of CKD: The Way of the Future?
  68. MO245: Risk Factors for Venous Thrombosis in ANTI-PLA2R + VE AND−VE Primary Membranous Nephropathy: A 6-YEAR Retrospective Analysis
  69. MO480: Predictive Ability of Clinical Assessment Tools For >2 Weeks in-Hospital Stay Following Hip Fracture in Patients Living With CKD: Insights From a 7-Year Prospective Analysis
  70. MO699: Investigating Longer Term Antibody Response Following Covid-19 Vaccination in Patients Receiving Peritoneal Dialysis—a Single-Center Observational Study
  71. Kidney Replacement Therapy in the Intensive Care Unit
  72. Long‐term antibody response following COVID‐19 vaccination in patients receiving peritoneal dialysis
  73. Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance
  74. Quality assessment on the delivery of acute kidney replacement therapy in intensive care
  75. Indications and timing of renal replacement therapy initiation in the intensive care unit: An updated review
  76. UNEXPECTED FINDING OF SINGLE BIFID PAPILLARY MUSCLE ANOMALY IN A PATIENT PRESENTING WITH ANGINA PECTORIS
  77. Risk factors of venous thromboembolism in anti-PLA2R-positive and negative primary membranous nephropathy
  78. POS-318 PREDICTIVE ABILITY OF CLINICAL ASSESSMENT TOOLS FOR DELIRIUM FOLLOWING HIP FRACTURE IN PATIENTS LIVING WITH CKD: INSIGHTS FROM A 7-YEAR PROSPECTIVE ANALYSIS
  79. POS-489 RITUXIMAB VERSUS MODIFIED PONTICELLI REGIMEN IN THE MANAGEMENT OF MEMBRANOUS NEPHROPATHY: OUTCOMES FROM A 24-MONTH OBSERVATIONAL ANALYSIS
  80. To What Extent Does Frailty Influence the Risk of Developing Urolithiasis?
  81. Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease
  82. Frailty assessment in ANCA-associated vasculitis: current evidence and remaining uncertainties
  83. Concurrent presentation of IgG4-related tubulointerstitial nephritis and ANCA MPO crescentic glomerulonephritis
  84. Vitamin B12 and chronic kidney disease
  85. Intrinsic Kidney Pathology Following COVID-19 Infection in Children and Adolescents: A Systematic Review
  86. Acute interstitial nephritis following SARS-CoV-2 vaccination
  87. An Unusual Cause of AKI in a Kidney Transplant Patient with Merkel Cell Cancer
  88. Native and transplant kidney histopathological manifestations in association with COVID-19 infection: A systematic review
  89. New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review
  90. Etanercept-Induced Anti-Glomerular Basement Membrane Disease
  91. Is home hemodialysis a practical option for older people?
  92. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  93. MO090TRANSPLANT KIDNEY BIOPSY FINDINGS IN COVID-19: A SYSTEMATIC REVIEW
  94. MO1039HEALTH PROFESSIONAL PERSPECTIVES OF FRAILTY STATUS EVALUATION DURING PRE-TRANSPLANT ASSESSMENT
  95. MO533WHICH PARAMETERS BEST PREDICT POSITIVE COVID-19 STATUS FOLLOWING HIP FRACTURE FOR PATIENTS LIVING WITH CKD?
  96. ASPERGILLUS PROSTHETIC VALVE ENDOCARDITIS PRESENTING WITH ACUTE VISUAL LOSS IN AN IMMUNOCOMPETENT PATIENT
  97. POS-348 Predicting difficulties with direct home discharge following hip fracture for patients living with CKD: Insights from a 6-year prospective study
  98. POS-349 WHICH PARAMETERS BEST PREDICT REHOSPITALIZATION FROM A SECOND HIP FRACTURE EVENT FOR PATIENTS LIVING WITH CKD ADMITTED FOLLOWING HIP FRACTURE? A 6-YEAR PROSPECTIVE ANALYSIS
  99. Prognostic performance of clinical assessment tools following hip fracture in patients with chronic kidney disease
  100. Dexamethasone in Hospitalized Patients with Covid-19
  101. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  102. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
  103. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  104. Frailty and the Potential Kidney Transplant Recipient: Time for a More Holistic Assessment?
  105. Primary Ewing Sarcoma of the Lung: A Challenging Case
  106. Patient safety and the role of the Helsinki Declaration on Patient Safety in Anaesthesiology
  107. Effect of delayed secondary care referral on morbidity and mortality in idiopathic pulmonary fibrosis patients treated with antifibrotics
  108. An atypical presentation of subacute cutaneous lupus erythematous
  109. Survival after non-resection of colorectal cancer: the argument for including non-operatives in consultant outcome reporting in the UK
  110. Will endoscopic submucosal dissection (ESD) become the gold standard for laterally spreading tumors (LST)?
  111. Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93:1442–1451
  112. Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625–637
  113. Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?
  114. AB0996 Bone mineral density at different sites as a predictor of rib fractures: a case-control study
  115. Poster Abstracts
  116. Poster Abstracts
  117. PWE-326 Extending the scope of tem – effect of radiotherapy on outcome in locally excised t2 rectal cancer